Cryoport (MM) (NASDAQ:CYPT)
Historical Stock Chart
From Sep 2019 to Sep 2024
Calypte Biomedical and Earvin 'Magic' Johnson Commemorate World AIDS Day
December 1st
ALAMEDA, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Calypte Biomedical
Corporation (BULLETIN BOARD: CYPT) , the developer and marketer of the only two
FDA approved HIV-1 antibody tests for use with urine samples, today announced
that Calypte's Chairman Tony Cataldo and "Magic" Ervin Johnson spent December
1st, World AIDS Day, speaking on the importance of HIV/AIDS testing.
"World AIDS Day is the ideal time for everyone to commit to being tested," said
Johnson. "It's a day when we can take on the rampant spread of HIV one person
at a time," he added. Calypte's Chairman Anthony Cataldo stated, "Early
detection can significantly alter the quality of life, and can help prevent the
spread of HIV and can ultimately save lives."
Magic Johnson first appeared on NBC's Today Show followed by an interview on BET
and ABC radio. Both Mr. Cataldo and Mr. Johnson appeared on MSNBC and Fox News,
Your World with Neal Cavuto to discuss the company and highlight the need for
HIV/AIDS testing.
To access these events please go to the company's web site at
http://www.calypte.com/
About The Magic Johnson Foundation
The Magic Johnson Foundation was established in 1991 as a single-disease
organization that worked to raise funds for community-based organizations
dealing with HIV/AIDS education and prevention programs. The Foundation has
since responded to the growing need to address all aspects of our youth's lives
by expanding its mission. This expanded mission emphasizes the Foundation's
focus on supporting community-based organizations and developing programs that
serve the health, educational and social needs of those residing in inner-city
communities. In addition, the Foundation has made a strong commitment to raise
awareness about many of the health and social concerns that threaten
under-served communities.
About Calypte Biomedical
Calypte Biomedical Corporation, headquartered in Alameda, California, is a
public healthcare company dedicated to the development and commercialization of
urine-based diagnostic products and services for Human Immunodeficiency Virus
Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases.
Calypte's tests include the screening EIA and supplemental Western Blot tests,
the only two FDA-approved HIV-1 antibody tests that can be used on urine
samples, as well as an FDA-approved serum HIV-1 antibody Western Blot test. The
Company believes that accurate, non-invasive urine-based testing methods for HIV
and other infectious diseases may make important contributions to public health
by helping to foster an environment in which testing may be done safely,
economically, and painlessly.
Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of 1933, as
amended. Those statements include statements regarding the intent, belief or
current expectations of the Company and its management. Such statements reflect
management's current views, are based on certain assumptions and involve risks
and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited to,
our ability to obtain additional financing and access funds from our existing
financing arrangements that will allow us to continue our current and future
operations and whether demand for our product and testing service in domestic
and international markets will continue to expand. The Company undertakes no
obligation to publicly update these forward-looking statements to reflect events
or circumstances that occur after the date hereof or to reflect any change in
the Company's expectations with regard to these forward-looking statements or
the occurrence of unanticipated events. Factors that may impact the Company's
success are more fully disclosed in the Company's most recent public filings
with the U.S. Securities and Exchange Commission ("SEC"), including its annual
report on Form 10-K for the year ended December 31, 2002 and its subsequent
filings with the SEC.
Investor Relations Contact:
Tim Clemensen
212-843-9337
email:
DATASOURCE: Calypte Biomedical Corporation
CONTACT: Tim Clemensen, +1-212-843-9337, ,
for Calypte Biomedical Corporation
Web site: http://www.calypte.com/